Xiaobin Wu Sells 3,991 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 3,991 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $380.43, for a total value of $1,518,296.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Xiaobin Wu also recently made the following trade(s):

• On Monday, November 17th, Xiaobin Wu sold 3,991 shares of BeOne Medicines stock. The stock was sold at an average price of $380.43, for a total value of $1,518,296.13.
• On Thursday, November 13th, Xiaobin Wu sold 6,009 shares of BeOne Medicines stock. The stock was sold at an average price of $380.54, for a total value of $2,286,664.86.
• On Wednesday, November 12th, Xiaobin Wu sold 10,000 shares of BeOne Medicines stock. The shares were sold at an average price of $356.02, for a total transaction of $3,560,200.00.

BeOne Medicines Stock Performance

ONC stock traded down $10.13 during trading on Wednesday, reaching $353.79. The company had a trading volume of 233,501 shares, compared to its average volume of 390,707. The company has a market cap of $41.94 billion, a price-to-earnings ratio of 693.71 and a beta of 0.31. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $170.99 and a twelve month high of $385.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The firm has a 50-day simple moving average of $330.76 and a 200-day simple moving average of $293.59.

Institutional Trading of BeOne Medicines

A number of hedge funds have recently modified their holdings of the stock. Anchor Investment Management LLC purchased a new position in BeOne Medicines during the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $28,000. Daiwa Securities Group Inc. purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at approximately $35,000. Farther Finance Advisors LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at approximately $39,000. Finally, Signaturefd LLC acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at $49,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ONC shares. Morgan Stanley boosted their price objective on shares of BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Guggenheim boosted their price target on BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 7th. Royal Bank Of Canada increased their price objective on BeOne Medicines from $395.00 to $408.00 and gave the company an “outperform” rating in a report on Tuesday. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday, October 3rd. Finally, JPMorgan Chase & Co. upped their target price on BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $363.15.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.